Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Jiangsu Hansoh Pharmaceutical Co., Ltd.)"
Count: 95
Selected: 0
NCT IDTitle
NCT06359600A Study of HS-10501 Tablets in Healthy Subjects
NCT06301074The Phase I Study of HS-10509 in Chinese Adult Subjects
NCT06279286Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder
NCT06246565A Study of HS-10383 in Chinese Adult Subjects With Refractory or Unexplained Chronic Cough (RUCC)
NCT06210607A Trial of HS-10511 in Healthy Subjects
NCT06147570A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
NCT06118827A Study of HS-10518 in Healthy Female Participants
NCT06118021A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
NCT06118008A Study of HS-20094 in T2DM Participants
NCT06110663A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
NCT06092983A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383
NCT06049030A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT06033742A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects
NCT05964790Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia
NCT05953506Phase 1a Study in Healthy Participants
NCT05938179A Study of HS-10353 in Adult Participants With Major Depressive Disorder
NCT05937867A Phase II Study of HS-10353 in Participants With Postpartum Depression
NCT05911464A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors
NCT05779579Study of HS-10517 in Chinese Adult Participants
NCT05777109Comparing of the PK, PD, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
NCT05740956A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors
NCT05504213A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer
NCT05480592A Study of HS-10380 in Chinese Participants
NCT05435274Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer
NCT05435248Hase 1/2 Study of HS-10375 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
NCT05430386Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC
NCT05429723First-in-Human Study to Investigate the Safety and Tolerability and Pharmacokinetics of HS-10383
NCT05378178A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors
NCT05367778Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors
NCT05367765A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
NCT05367700A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.
NCT05353205A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
NCT05207787Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors
NCT05196971A Study To Evaluate The Safety, Tolerability And Pharmacokinetics of HS-10345 In Treatment-Resistant Depression
NCT05195203A Study of HS-10353 in Chinese Participants.
NCT05116410A Study of HS-20094 in Healthy Participants
NCT05044988A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer
NCT04986436Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of HS-10360 in Healthy Subjects.
NCT04951648A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation
NCT04951635A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
NCT04923906Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations
NCT04881006Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions
NCT04880993Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions
NCT04804267Evaluation of Clinical Equivalence Between Two Linaclotide Products in the Treatment of Chronic Idiopathic Constipation
NCT04687241Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
NCT04652297Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers
NCT04631835Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
NCT04494373Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of HS-20090 and Xgeva® in Healthy Adults
NCT04477096Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine
NCT04477057PhaseⅠStudy of the HS-10241 in Patients With Advanced Solid Tumors